Nancies. J Clin Oncol 2001; 19: 3267?279. 25. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039?043. 26. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFRmutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2: 922?33. 27. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609?619. 28. Pao W, Miller VA. Epidermal growth aspect receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556?568. 29. Janne PA, Johnson BE. Effect of epidermal development aspect receptor tyrosine kinase domain mutations on the outcome of sufferers with non-small cell lung cancer treated with epidermal development element receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12: 4416s?420s. 30. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. BIBW2992, an irreversible EGFR/HER2 inhibitor very effective in preclinical lung cancer models. Oncogene 2008; 27: 4702?711. 31. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070?074. 32. Wong KK. HKI-272 in non small cell lung cancer. Clin Cancer Res 2007; 13: s4593 4596. 33. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal development aspect receptor 1 (EGFR) and two (HER2) tyrosine kinase within a 2-week on, 2-week off schedule in sufferers with sophisticated solid tumours. Br J Cancer 2008; 98: 80?5. 34. Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Kluter S et al. Chemogenomic profiling offers insights in to the restricted activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Formula of 1338377-73-3 Cancer Res 2010; 70: 868?74.4-Ethynyl-1,2-dimethylbenzene Chemscene 35.PMID:36014399 Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892?899. 36. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al. Gefitinib in mixture with gemcitabine and cisplatin in sophisticated non-small-cell lung cancer: a phase III trial NTACT 1. J Clin Oncol 2004; 22: 777?84. 37. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al. Gefitinib in combination with paclitaxel and carboplatin in sophisticated non-small-cell lung cancer: a phase III trial NTACT two. J Clin Oncol 2004; 22: 785?94. 38. Minucci S, Pelicci PG. Histone deacetylase inhibitors plus the guarantee of epigenetic (and more) therapies for cancer. Nat Rev Cancer 2006; six: 38?1. 39. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer therapy. Eur J Pharmacol 2009; 625: 131?42. 40. Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13: 18?six. 41. Dowdy SC, Jiang S,.